Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 15.9474
- Book/Share 10.5137
- PB 3.6105
- Debt/Equity 1.0992
- CurrentRatio 0.8363
- ROIC 0.1128
- MktCap 78646302373.8344
- FreeCF/Share 2.9515
- PFCF 13.2107
- PE 14.2863
- Debt/Assets 0.2894
- DivYield 0.0316
- ROE 0.2972
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GSK | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | GSK | Barclays | Equal Weight | Underweight | -- | -- | Jan. 6, 2026 |
| Upgrade | GSK | BofA Securities | Underperform | Neutral | -- | -- | Nov. 25, 2025 |
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
GSK beat the numbers, but the real story was the guidance
Published: February 04, 2026 by: Proactive Investors
Sentiment: Positive
A clean fourth-quarter beat pushed GSK ahead of its own medium-term targets. Yet management chose to set a deliberately modest bar for 2026, leaving investors to decide whether this is prudence or opportunity.
Read More
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Positive
GSK's Q4 earnings and sales top estimates as strong specialty medicine demand fuels growth and drives shares higher on an upbeat 2026 outlook.
Read More
Why GSK (GSK) is a Top Value Stock for the Long-Term
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path
Published: February 02, 2026 by: Benzinga
Sentiment: Positive
On Monday, Wave Life Sciences Ltd. (NASDAQ: WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE: GSK).
Read More
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why GSK (GSK) is a Strong Momentum Stock
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Positive
GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.
Read More
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Neutral
Bristol Myers Squibb BMY and GSK PLC GSK are among the largest global biopharma companies with broad and diverse portfolios.
Read More
Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK
Published: January 20, 2026 by: GlobeNewsWire
Sentiment: Neutral
NAARDEN, The Netherlands, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that GSK (NYSE: GSK) has entered into a definitive agreement to acquire Forbion Growth Fund III portfolio company RAPT Therapeutics, Inc. (NASDAQ: RAPT) in a transaction valued at $2.2 billion.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
GSK is next to agree drug pricing deal with US government
Published: December 22, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC (LSE:GSK, NYSE:GSK) has become the latest big pharma company to fall into line with the US government's "most favoured nation" drug pricing regime, in exchange for an exemption from tariffs. The FTSE 100 group said the voluntary agreement with the White House implements all four policy actions requested by President Trump earlier this year.
Read More
Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln
Published: December 21, 2025 by: Reuters
Sentiment: Positive
South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.
Read More
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Published: December 21, 2025 by: PRNewsWire
Sentiment: Neutral
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK …
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
Read More
UK approves GSK's twice-yearly asthma drug
Published: December 15, 2025 by: Reuters
Sentiment: Positive
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults.
Read More
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Read More
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
Read More
GSK gets EU regulator backing for expanded use of RSV vaccine
Published: December 12, 2025 by: Reuters
Sentiment: Positive
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.
Read More
European health regulator recommends approval for GSK's twice yearly asthma drug
Published: December 12, 2025 by: Reuters
Sentiment: Positive
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
Read More
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
Read More
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why GSK (GSK) is a Top Value Stock for the Long-Term
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Luke Victor Miels
- Employees 68629